Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > first quarter of 2022

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson Aug 31, 2021 10:31am

89 Views

Post# 33787487

RE: first quarter of 2022

Expects!! We have heard this word come up a lot with Clas, I hope they stick to their words!!

whisky11 wrote:

...Claritas expects to complete a Phase 1 clinical study of R-107 by the first quarter of 2022, and to also complete a pilot Phase 2a clinical study of R-107 in hospitalized PAH patients in 2022....